STOCK TITAN

Evotec SE American Depositary Shares - EVO STOCK NEWS

Welcome to our dedicated page for Evotec SE American Depositary Shares news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec SE American Depositary Shares stock.

Evotec SE, headquartered in Hamburg, Germany, is a leading global drug discovery and development company. Specializing in providing comprehensive solutions to pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations, Evotec is renowned for its extensive capabilities in therapeutic areas such as central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health.

Evotec’s core business is divided into two main segments: Shared R&D and Just-Evotec Biologics. The Shared R&D segment, making up approximately 80% of the company's sales, offers drug discovery and manufacturing services on a fee-for-service basis. It also engages in integrated drug discovery collaborations leveraging proprietary, internally-developed assets. Just-Evotec Biologics, accounting for about 20% of sales, provides contract development and manufacturing (CDMO) services for biologics.

With a workforce of over 5,000 employees, Evotec operates 18 production sites mainly across Europe and the United States. In recent years, the company has made significant strides in forming strategic alliances and collaborations, such as the recent partnership with Claris Ventures and Variant Bio, aimed at accelerating the development of innovative therapeutics.

Evotec’s multimodal platform combines cutting-edge technologies, data, and scientific expertise to drive the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. The company’s integrated R&D network includes partnerships with all Top 20 Pharma companies and over 800 biotech companies, academic institutions, and other healthcare stakeholders. This robust network facilitates the co-creation of a world-leading pipeline of over 200 proprietary and co-owned R&D projects, ranging from early discovery to clinical development.

Recent achievements by Evotec include the successful Clinical Trial Application (CTA) for IAMA Therapeutics’ lead program IAMA-6 and the strategic collaboration with Janssen for immune-based therapies. Additionally, Evotec has expanded its relationship with Bristol Myers Squibb in neurodegeneration and targeted protein degradation.

Financially, Evotec has demonstrated resilience despite macroeconomic challenges and a substantial cyber-attack in 2023. The company reported a 4% increase in revenues, reaching €781.4 million in 2023, driven by new collaborations and the strong performance of Just-Evotec Biologics.

As of 2024, Evotec continues to focus on sustainable and profitable growth, optimizing its operations to meet evolving market demands. The company is committed to advancing its mission of discovering and developing effective therapeutics that address unmet medical needs globally.

Rhea-AI Summary

Evotec has partnered with Hannover Medical School to create a molecular patient database for Sjogren's syndrome and systemic lupus erythematosus. The collaboration aims to enhance disease understanding through a unique longitudinal PanOmics database by analyzing biospecimens from hundreds of patients. Evotec will commercially exploit the data, while MHH will use it for academic research. This partnership could facilitate the development of personalized therapies for autoimmune diseases, addressing unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.54%
Tags
partnership
-
Rhea-AI Summary

Evotec SE launched its PanOmics data analysis platform, PanHunter, at Bio-IT World on October 18, 2022. This software-as-a-service (SaaS) product aims to empower scientists by providing comprehensive access to vast PanOmics data sets, accelerating R&D processes and improving drug discovery success rates. With a significant increase in publicly available PanOmics data, PanHunter is designed to stratify patient populations and predict drug efficacy and toxicity, marking a notable advancement in data-driven medicine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
none
-
Rhea-AI Summary

Evotec and Toronto Innovation Acceleration Partners (TIAP) have expanded their LAB150 partnership to include Amgen as a strategic partner, committing a combined investment of US$ 14 million. This collaboration aims to enhance the development of Canada's life science companies by streamlining the transition from academic research to market-ready products. LAB150 has evaluated over 150 projects and currently supports 10 projects. Amgen will provide financial backing and mentorship to these initiatives, accelerating commercialization efforts and fostering innovation in the sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.54%
Tags
partnership
Rhea-AI Summary

Evotec SE (NASDAQ: EVO) and Toronto Innovation Acceleration Partners (TIAP) announced the expansion of their LAB150 partnership to include Amgen, with a combined investment of US$14M. This partnership aims to enhance the efficiency of academic research in Canada, focusing on drug discovery and commercialization. Amgen will provide mentorship and evaluate LAB150 projects for venture investment. Since its inception in 2017, LAB150 has supported over 150 projects with US$7M in investments. The partnership is expected to accelerate the formation of life science companies in Canada, strengthening its biotech ecosystem.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.54%
Tags
partnership
-
Rhea-AI Summary

Evotec SE announced a contract with the U.S. Department of Defense valued up to $49.9 million for the rapid development of monoclonal antibody drug prototypes targeting plague. Under this contract, Just - Evotec Biologics will advance mAb prototypes from initial discovery to Phase I clinical trials using its J.DESIGN platform, which integrates AI and machine learning. The goal is to produce effective medical countermeasures against plague, enhancing national security. The work will take place at Evotec's Redmond, Washington facility, part of the DOD's Advanced Development and Manufacturing network.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
none
-
Rhea-AI Summary

Evotec has begun construction of its J.POD ® biologics manufacturing facility in Toulouse, France, expected to be operational in H2 2024. This facility will utilize advanced J.POD ® technology to enhance clinical and commercial manufacturing capacity for biologics, addressing challenges in traditional manufacturing methods. The project is backed by funding from the French government and the Occitanie Region and is anticipated to create over 150 high-skill jobs in the area.

Evotec operates globally and focuses on the development of therapeutics across various medical areas.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
none
Rhea-AI Summary

Evotec SE has announced its acquisition of Central Glass Germany GmbH from Central Glass Co. Ltd., enhancing its drug substance manufacturing capabilities. The fully operational facility in Halle/Westphalia, with a team of ~60 chemists, is EU cGMP certified, covering over 5,000 square meters. This strategic move aligns with Evotec's commitment to rare diseases and precision medicine, aiming for earnings accretion by 2023/24. The contract, signed on August 24, 2022, was at a purchase price of €1, and the transaction is set to close on November 1, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
-
Rhea-AI Summary

Evotec SE and Alpine Immune Sciences have expanded their partnership to develop a commercial manufacturing process for ALPN-303, a dual BAFF/APRIL inhibitor. This collaboration builds on their ongoing first-in-human program initiated in 2020, with Evotec providing drug substance materials for clinical studies. The enhanced contract will utilize Evotec's J.DESIGN technology platform in Redmond, Washington, aiming to improve outcomes for patients with systemic lupus erythematosus and other autoimmune diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.08%
Tags
partnership
-
Rhea-AI Summary

Evotec SE will release its financial results for the first half of 2022 on August 11, 2022. A conference call will be held at 02:00 PM CEST to discuss the outcomes and company performance. Dial-in details are provided for various countries, and a webcast with presentation slides will also be available on their website. Evotec is a life science company focused on developing innovative therapeutics across multiple therapeutic areas, boasting over 200 proprietary projects in its pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
none
Rhea-AI Summary

Boehringer Ingelheim, Evotec, and bioMérieux have formed a joint venture named Aurobac Therapeutics SAS to combat Antimicrobial Resistance (AMR). Funded by Boehringer with 30 million EUR and 5 million EUR each from Evotec and bioMérieux, the venture aims to develop new antimicrobials and diagnostics. AMR poses a significant global health threat, with antibiotic-resistant infections causing around 1.27 million deaths annually. Aurobac seeks to implement precision medicine approaches and new economic models to enhance treatment strategies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
none

FAQ

What is the current stock price of Evotec SE American Depositary Shares (EVO)?

The current stock price of Evotec SE American Depositary Shares (EVO) is $5.35 as of November 21, 2024.

What is the market cap of Evotec SE American Depositary Shares (EVO)?

The market cap of Evotec SE American Depositary Shares (EVO) is approximately 1.9B.

What is Evotec SE?

Evotec SE is a global drug discovery and development company headquartered in Hamburg, Germany. It provides comprehensive solutions in drug discovery and manufacturing to pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations.

What are Evotec's main business segments?

Evotec's business is divided into Shared R&D, which offers drug discovery and manufacturing services, and Just-Evotec Biologics, which provides CDMO services for biologics.

Who are Evotec's partners?

Evotec collaborates with all Top 20 Pharma companies, over 800 biotech companies, academic institutions, and other healthcare stakeholders.

What recent collaborations has Evotec entered into?

Recent collaborations include partnerships with Claris Ventures to accelerate programs into the clinic and with Variant Bio to develop treatments for fibrotic diseases.

How many employees does Evotec have?

Evotec employs over 5,000 people across 18 production sites in Europe and the United States.

What are Evotec's key therapeutic areas?

Evotec focuses on central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health.

What financial performance did Evotec report in 2023?

Evotec reported a 4% increase in revenues, reaching €781.4 million in 2023, despite challenging economic conditions and a cyber-attack.

What are the future goals of Evotec?

Evotec aims to focus on sustainable and profitable growth, optimizing its operations and continuing to advance its mission of developing effective therapeutics.

What is Just-Evotec Biologics?

Just-Evotec Biologics is a segment of Evotec that offers contract development and manufacturing services for biologics.

What makes Evotec's platform unique?

Evotec’s multimodal platform combines innovative technologies, data, and scientific expertise to drive the discovery, development, and production of first-in-class and best-in-class pharmaceutical products.

Evotec SE American Depositary Shares

OTC:EVO

EVO Rankings

EVO Stock Data

1.88B
354.61M
2.34%
0.06%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Hamburg